188 related articles for article (PubMed ID: 4593892)
1. Biopharmaceutical aspects of the design of steroidal dosage forms.
Short MP; Rhodes CT
Pharmazie; 1973 Aug; 28(8):509-13. PubMed ID: 4593892
[No Abstract] [Full Text] [Related]
2. Drug formulation and biologic availability.
Poole JW
Semin Drug Treat; 1971 Sep; 1(2):148-76. PubMed ID: 5153883
[No Abstract] [Full Text] [Related]
3. Partitioning phenomena in dosage form and biopharmaceutical design. II. Some partitioning considerations in dosage form design.
Schumacher GE
Am J Hosp Pharm; 1971 Dec; 28(12):985-8. PubMed ID: 5135196
[No Abstract] [Full Text] [Related]
4. [Comparative biopharmaceutical study of tegalide].
Lopatina NB; Lebedeva MN
Med Parazitol (Mosk); 2000; (1):27-9. PubMed ID: 10808715
[TBL] [Abstract][Full Text] [Related]
5. [The role of biopharmaceutical parameters in drug development (author's transl)].
Thoma K
Arzneimittelforschung; 1976; 26(1A):121-9. PubMed ID: 947191
[TBL] [Abstract][Full Text] [Related]
6. Factors influencing the formulation of semisolid preparations with special reference to corticosteroid products.
Worthington HE
Acta Derm Venereol Suppl (Stockh); 1973; 53():29-34. PubMed ID: 4518660
[No Abstract] [Full Text] [Related]
7. Partitioning phenomena in dosage form and biopharmaceutical design. 3. Some partitioning considerations in drug absorption, distribution, response and elimination.
Schumacher GE
Am J Hosp Pharm; 1972 Apr; 29(4):339-43. PubMed ID: 5025265
[No Abstract] [Full Text] [Related]
8. Partitioning phenomena in dosage form and biopharmaceutical design. I. Prognostic significance of partition coefficients.
Am J Hosp Pharm; 1971 Oct; 28(10):796-9. PubMed ID: 5125175
[No Abstract] [Full Text] [Related]
9. Biopharmaceutical implications of compaction and consolidation in the design of drug dosage forms.
Rees JE
Boll Chim Farm; 1978 Jul; 117(7):375-90. PubMed ID: 743383
[No Abstract] [Full Text] [Related]
10. Pickering w/o emulsions: drug release and topical delivery.
Frelichowska J; Bolzinger MA; Valour JP; Mouaziz H; Pelletier J; Chevalier Y
Int J Pharm; 2009 Feb; 368(1-2):7-15. PubMed ID: 18992799
[TBL] [Abstract][Full Text] [Related]
11. Penetration and action of glucocorticoids.
Schlagel CA
Adv Biol Skin; 1972; 12():339-56. PubMed ID: 4579200
[No Abstract] [Full Text] [Related]
12. Biopharmaceutical studies of oral formulations containing propyphenazone.
Shekerdjiiski R; Paskov V; Lambov N; Gencheva P; Rachev D; Titeva S; Minkov E
Pharmazie; 1987 Mar; 42(3):184-6. PubMed ID: 3602076
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of action of tablet disintegrants.
Lowenthal W
Pharm Acta Helv; 1973; 48(11):589-609. PubMed ID: 4593513
[No Abstract] [Full Text] [Related]
14. [Biopharmaceutical aspects of oral dosage forms].
Ross G; Hiller D
Pharm Unserer Zeit; 1974 Sep; 3(5):153-61. PubMed ID: 4408669
[No Abstract] [Full Text] [Related]
15. Solubility behavior and biopharmaceutical classification of novel high-solubility ciprofloxacin and norfloxacin pharmaceutical derivatives.
Breda SA; Jimenez-Kairuz AF; Manzo RH; Olivera ME
Int J Pharm; 2009 Apr; 371(1-2):106-13. PubMed ID: 19150493
[TBL] [Abstract][Full Text] [Related]
16. [Influence of dosage form on drug effect].
Zathurecký L
Pharmazie; 1972 Nov; 27(11):686-93. PubMed ID: 4650983
[No Abstract] [Full Text] [Related]
17. [Surfactants in dosage forms and biological systems. Part II].
Eros I
Acta Pharm Hung; 2005; 75(3):161-7. PubMed ID: 16318240
[TBL] [Abstract][Full Text] [Related]
18. [Biological and in vitro availability].
Speiser P
Pharm Acta Helv; 1971 Aug; 46(8):449-67. PubMed ID: 5092965
[No Abstract] [Full Text] [Related]
19. [Bioavailability of various steroids administered orally].
Bruni G; Galletti F
Boll Chim Farm; 1973 Feb; 112(2):110-5. PubMed ID: 4719966
[No Abstract] [Full Text] [Related]
20. [Biopharmaceutical aspects of scientific research and the teaching of drug technology].
Murav'ev IO
Farm Zh; 1977; (2):38-45. PubMed ID: 328295
[No Abstract] [Full Text] [Related]
[Next] [New Search]
